Patient Derived Acute Myeloid Leukemia (AML) Models and Studies

 

REQUEST A QUOTE

 

 

micetech@jax.org | 1.800.422.6423 (US) | 1.207.288.5845 (International)

Contact Technical Support Live Chat Offline

Model Specifications

Summary of AML Model Specifications

J000096994 Data

J000096994 is an Aggressive AML, Positive for FLT3-ITD

 aml-studies

AML J000096944 

AML Studies

PDX J000096994 has engraftment levels greater than 5% AML in the peripheral blood of NSG™-SGM3 mice 12-16 weeks post engraftment.

JAX AML model J000096994 displays Positive Response to the AML Standard of Care Treatment Ara-C

AML Studies

J000096994 AML NSGTM-SGM3 mice are a robust preclinical model for AML.

Left panel: Growth rate of AML samples detected in peripheral blood in the presence or absence of arabinofuranosyl cytidine (Ara-C). Mice were engrafted with human AML cells (hCD33+) and treated with +/- Ara-C (30 mg/kg) for five consecutive days.

Right panel: Average engraftment levels at terminus are shown for blood, bone marrow, and spleen samples.

J000106132* Data

J000106132*, Positive for FLT3, NPM1, DNMT3A and IDH1

*Passaged Model

 aml-studies

    Percent Engraftment of AML J000106132

aml studies

PDX J000106132 averages 20% engraftment at 6 weeks and 70% at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

ARA-C RESPONSE IN AML MODEL J000106132

aml-studies

J000106132 AML NSG™-SGM3 mice. Growth rate of AML samples detected in
peripheral blood in the presence or absence of Ara-C.  Mice were engrafted with
human AML cells (hCD33+) and treated +/- Ara-C (30mg/kg) for five consecutive days.

J000106134* Data

J000106134*, Positive for FLT3 and NPM1

*Passaged Model

 AML Studies

    Percent Engraftment of AML J000106134

AML Studies

PDX J000106134 averages 45% engraftment at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

ARA-C RESPONSE IN AML MODEL J000106134

aml-studies

J000106134 AML NSG™-SGM3 mice. Growth rate of AML samples detected in
peripheral blood in the presence or absence of Ara-C.  Mice were engrafted with human
AML cells (hCD33+) and treated +/- Ara-C (30mg/kg) for five consecutive days.

J000106566* Data

J000106566*, Positive for TP53

*Passaged Model

 AML Studies

    Percent Engraftment of AML J000106566

AML Studies

PDX J000106566 averages 10% engraftment at 6 weeks and 35% at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

              ARA-C RESPONSE IN AML MODEL J000106566

aml-studies

J000106566 AML NSG™-SGM3 mice. Growth rate of AML samples detected in
peripheral blood in the presence or absence of Ara-C.  Mice were engrafted with
human AML cells (hCD33+) and treated +/- Ara-C (30mg/kg) for five consecutive days.

J000096828 Data

J000096828, No Mutations Identified

 AML Studies

    Percent Engraftment of AML J000096828

aml-studies

PDX J000096828 averages 16% engraftment at 10 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000096896 Data

J000096896, Positive for FLT3 and IDH2 Mutations

 AML Studies

    Percent Engraftment of AML J000096896

aml-studies

PDX J000096896 averages 7% engraftment at 10 weeks post engraftment and 14% at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106124* Data

J000106124*, No Mutations Identified

*Passaged Model

 AML Studies

    Percent Engraftment of AML J000106124

AML Studies

PDX J000106124 averages 80% engraftment at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106143* Data

J000106143*, Positive for FLT3 ITD, FLT3 TKD, and NPM1

*Passaged Model

 aml studies

    Percent Engraftment of AML J000106143

AML Studies

PDX J000106143 averages 50% engraftment at 12 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106565* Data

J000106565*, Positive for FLT3 ITD, FLT3 TKD, and NPM1

*Passaged Model

 AML Studies

       Percent Engraftment of AML J000106565

AML Studies

PDX J000106565 averages 15% engraftment at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106569* Data

J000106569*, Positive for FLT3-ITD and NPM1

*Passaged Model

 AML Studies

    Percent Engraftment of AML J000106569

AML Studies

PDX J000106569 averages 10% engraftment at 8 weeks and 57% at 12 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

FAQ & References

Frequently Asked Questions

In which mouse models were engraftment levels tested?

The currently available models are confirmed to engraft in the NSG™-SGM3 mice.

What engraftment levels do you typically see?

Greater than 5% AML in the peripheral blood of NSG™-SGM3 mice 10-16 weeks post engraftment.

How many AML engrafted mice can be included per order or on study with JAX?

A minimum of 15 mice is required. Approximately 100-500 mice in total can be engrafted depending on the model of interest.

What are passaged AML models?

Some AML tumor models in our portfolio were passaged in vivo. This approach allows JAX to continuously supply the models and retain inventory for use in further studies at later dates if needed.

How long does it take to confirm AML engraftment?

The average time to confirm AML engraftment in the peripheral blood of NSG™-SGM3 mice is 8 weeks post injection. 

References

Elizabeth C. Townsend, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in
         Mice, Cancer Cell, Volume 29, Issue 4, 2016, Pages 574-586, ISSN 1535-6108

Wunderlich et al. 2010. Leukemia. 24(10):1785-8. [PMID: 20686503]